Unlock instant, AI-driven research and patent intelligence for your innovation.

Ranolazine effervescent tablets and preparation method thereof

A technology of ranolazine and effervescent tablets, which is applied in pharmaceutical formulations, medical preparations without active ingredients, and medical preparations containing active ingredients, etc., can solve problems such as affecting cardiac electrical conduction and prolonging QT interval.

Inactive Publication Date: 2018-05-04
FOSHAN TENGRUI MEDICINE TECH CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have shown that it can partially inhibit fatty acid oxidation, but at the same time it can also affect the electrical conduction of the heart, causing dose-related QT interval prolongation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment l

[0025] Ranolazine 250g

[0026] Sucrose 550g

[0027] Tartaric acid 60g

[0028] Sodium bicarbonate 60g

[0029] Disodium Glycyrrhizinate 60g

[0030] Orange Flavor 33g

[0031] Scarlet Red 32g

[0032] Talc powder 55g

[0033] A total of 1000 pieces were made

[0034] Preparation method: mix 200-mesh ranolazine powder and 200-mesh lactose powder in equal increments; add the remaining excipient fillers, organic acids, inorganic bases, flavoring agents, taste-masking agents, coloring agents and lubricants in equal increments After mixing evenly, pass through a 200-mesh sieve; add it to the mixed powder of ranolazine and lactose, mix evenly according to the method of equal increments, and then directly compress into tablets.

Embodiment 2

[0036] Ranolazine 25g

[0037] Lactose 510g

[0038] Citric acid 75 g

[0039] Sodium carbonate 75g

[0040] Aspartame 7.5g

[0041] Glycyrrhizin 10 g

[0042] Peach Flavor 72.5g

[0043] Orange 75g

[0044] Micronized silica gel 75g

[0045] A total of 1000 pieces were made

[0046] Preparation method: with embodiment 1.

Embodiment 3

[0048] Ranolazine 100g

[0049] Sucrose 515g

[0050] Tartaric acid 85g

[0051] Sodium bicarbonate 85g

[0052] Disodium Glycyrrhizinate 60 g

[0053] Orange Flavor 75g

[0054] Scarlet Red 75g

[0055] Talc powder 65g

[0056] A total of 1000 pieces were made

[0057] Preparation method: with embodiment 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to ranolazine effervescent tablets and a preparation method thereof. The invention aims to provide a new preparation, namely the ranolazine effervescent tablet, for patients andmedical workers. The ranolazine effervescent tablets are rapid in disintegration, rapid in absorption, high in bioavailability, convenient to take, few in intestinal residue and small in side effect.The ranolazine effervescent tablets are prepared by taking ranolazine as a raw material and adding auxiliary materials with specific varieties and proportion and according to the technological means of the invention. The product is sweet, has fragrance, is quick in response and high in bioavailability, and particularly can improve the medication compliance of patients easily.

Description

technical field [0001] The invention relates to a ranolazine effervescent tablet and a preparation method thereof. Background technique [0002] Ranolazine has anti-angina pectoris and anti-myocardial ischemia effects, but its specific mechanism of action is still unclear. Studies have shown that it can partially inhibit fatty acid oxidation, but at the same time it can also affect the electrical conduction of the heart, causing dose-related QT interval prolongation. Ranolazine is limited to the use of long-acting nitrates, calcium ion channel blockers and β2 receptor blockers and other anti-angina drugs ineffective. Clinical trials have shown that ranolazine is more effective in male patients than in females, [0003] Long-term use can cause adverse reactions such as dizziness, headache, constipation and nausea. [0004] Ranolazine, a new chemical entity, is the first FDA-approved drug for the treatment of chronic angina in a decade. Different from the existing antiangi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/46A61K31/495A61K47/26A61K47/24A61K47/46A61P9/10
CPCA61K31/495A61K9/2009A61K9/2013A61K9/2018A61K9/2068A61K9/2095
Inventor 欧泽桂
Owner FOSHAN TENGRUI MEDICINE TECH CO LTD